GCM
PRCT icon

Ghisallo Capital Management’s Procept Biorobotics PRCT Stock Holding History

Ghisallo Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-55,000
Closed -$1.38M – 377
2021
Q4 		$1.38M Hold
55,000
– – 0.07% 349
2021
Q3 		$2.1M Buy
+55,000
New +$2.11M 0.08% 280

Other funds holding PRCT

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ghisallo Capital Management's PRCT Position: Q1 2022 in Review

Ghisallo Capital Management sold out of Procept Biorobotics (PRCT) in Q1 2022, closing a stake of 55,000 shares — an estimated $1.38M sold.

Ghisallo Capital Management first reported a position in PRCT in Q3 2021 and held it in 2 quarters. The position peaked at $2.1M in Q3 2021. 58 funds tracked by Wall St. Rank hold PRCT as of Q1 2022.

  • Ghisallo Capital Management reported no remaining Procept Biorobotics position as of Q1 2022 after selling out during the quarter.
  • Ghisallo Capital Management sold 55,000 Procept Biorobotics shares in Q1 2022, an estimated $1.38M.
  • Ghisallo Capital Management first reported a position in Procept Biorobotics in Q3 2021 and held it in 2 quarters.
  • Ghisallo Capital Management's Procept Biorobotics position peaked at $2.1M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2022.

Based on Ghisallo Capital Management's 13F filing for Q1 2022, filed 10 May 2022.